Literature DB >> 24757249

FGF23 in type 2 diabetic patients: relationship with bone metabolism and vascular disease.

Rebeca Reyes-Garcia1, Antonia Garcia-Martín, Beatriz García-Fontana, Sonia Morales-Santana, Pedro Rozas-Moreno, Manuel Muñoz-Torres.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24757249     DOI： 10.2337/dc13-2235

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  12 in total

Review 1.  The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.

Authors:  Maitane Izaguirre; María J Gil; Ignacio Monreal; Fabrizio Montecucco; Gema Frühbeck; Victoria Catalán
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

2.  The role of RANKL and FGF23 in Assessing Bone Turnover in Type 2 Diabetic Patients.

Authors:  G Niță; O Niță; A Gherasim; L I Arhire; A M Herghelegiu; L Mihalache; C Tuchilus; M Graur
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 1.104

3.  Insulin suppresses the production of fibroblast growth factor 23 (FGF23).

Authors:  Ludmilla Bär; Martina Feger; Abul Fajol; Lars-Oliver Klotz; Shufei Zeng; Florian Lang; Berthold Hocher; Michael Föller
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-14       Impact factor: 11.205

4.  Relationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing Parathyroidectomy.

Authors:  Hung-Wei Liao; Peir-Haur Hung; Chih-Yen Hsiao; Hung-Hsiang Liou; Hsin-Shih Lin; Tsang-Hai Huang; I-Ming Jou; Kuen-Jer Tsai
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

5.  FGF-23/Vitamin D Axis in Type 1 Diabetes: The Potential Role of Mineral Metabolism in Arterial Stiffness.

Authors:  Gemma Llauradó; Ana Megia; Albert Cano; Olga Giménez-Palop; Inmaculada Simón; Montserrat González-Sastre; Eugenio Berlanga; Sonia Fernández-Veledo; Joan Vendrell; José-Miguel González-Clemente
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

Review 6.  FGF23, Biomarker or Target?

Authors:  Cristian Rodelo-Haad; Rafael Santamaria; Juan R Muñoz-Castañeda; M Victoria Pendón-Ruiz de Mier; Alejandro Martin-Malo; Mariano Rodriguez
Journal:  Toxins (Basel)       Date:  2019-03-22       Impact factor: 4.546

Review 7.  Cytokines and Abnormal Glucose and Lipid Metabolism.

Authors:  Jie Shi; Jiangao Fan; Qing Su; Zhen Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-30       Impact factor: 5.555

8.  The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease.

Authors:  Hodaka Yamada; Makoto Kuro-O; Kazuo Hara; Yuichiro Ueda; Ikuyo Kusaka; Masafumi Kakei; San-E Ishikawa
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240

9.  Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes.

Authors:  Xiang Hu; Xiaojing Ma; Yuqi Luo; Yiting Xu; Qin Xiong; Xiaoping Pan; Yuqian Bao; Weiping Jia
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

10.  Association between Urinary Calcium Excretion and Estimated Glomerular Filtration Rate Decline in Patients with Type 2 Diabetes Mellitus: A Retrospective Single-center Observational Study.

Authors:  Hodaka Yamada; Shunsuke Funazaki; Daisuke Suzuki; Rika Saikawa; Masashi Yoshida; Masafumi Kakei; San-E Ishikawa; Yoshiyuki Morisita; Kazuo Hara
Journal:  J Clin Med       Date:  2018-07-10       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.